Eslicarbazepine Acetate (BIA 2 093) as Therapy for Refractory Partial Seizures in Children
Efficacy and Safety Study of Eslicarbazepine Acetate (BIA 2 093) as Adjunctive Therapy for Refractory Partial Seizures in Children
Sponsor: Bial - Portela C S.A.
A PHASE3 clinical study on Partial Epilepsy in Children and Adolescents, this trial is completed. The trial is conducted by Bial - Portela C S.A. and has accumulated 10 data snapshots since 2007. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE3
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE3
▶ Show 5 earlier versions
-
Jan 2021 — Dec 2022 [monthly]
Completed PHASE3
-
Dec 2018 — Jan 2021 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Jun 2018 — Dec 2018 [monthly]
Active Not Recruiting PHASE3
-
Oct 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE3
-
Jan 2017 — Oct 2017 [monthly]
Active Not Recruiting PHASE3
First recorded
Dec 2007
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Bial - Portela C S.A.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Amiens, France , Banja Luka, Bosnia and Herzegovina , Barcelona, Spain , Belgrade, Serbia , Birmingham, United Kingdom , Bordeaux, France , Brno, Czechia , Bucharest, Romania , Budapest, Hungary , Cagliari, Italy and 65 more locations